Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: The Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study

Journal of Internal Medicine

Volumn 257, Issue 3, 2005, Pages 255-262

  Virtanen, Jyrki K ^a   Voutilainen, S ^a   Alfthan, G ^b   Korhonen, M J ^a   Rissanen, T H ^a   Mursu, J ^a   Kaplan, G A ^c   Salonen, J T ^a,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Oy Jurilab Ltd   (Finland)

Author keywords

Cardiovascular disease; Homocysteine; Interaction; Prospective studies; Risk factors

Indexed keywords

APOLIPOPROTEIN B; FIBRINOGEN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FIBRINOGEN BLOOD LEVEL; FINLAND; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SERUM; SMOKING;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; EPIDEMIOLOGIC METHODS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; SMOKING;

EID: 14844322322     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01450.x     Document Type: Article

References (31)

1. Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112: 556-65.
2. Voutilainen S, Lakka TA, Hämelahti P, Lehtimäki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med 2000; 248: 217-22.
3. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
4. Knekt P, Reunanen A, Alfthan G et al. Hyperhomocystinemia. A risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161: 1589-94.
5. Woo KS, Chook P, Lolin Y et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-4.
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
7. Glueck CJ, Shaw P, Land JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-6,
8. Schlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000; 153: 383-9.
9. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 1042-5.
10. O'Callaghan P, Meleady R, Fitzgerald T, Graham I, the European COMAC group. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580-6.
11. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263-70.
12. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
13. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988; 20: 46-50.
14. Schwab U, Törrönen A, Toppinen L et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76: 961-7.
15. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-11.
16. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfraction, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 1991; 84: 129-39.
17. Salonen JT, Seppänen K, Nyyssönen K et al. Intake of mercury from fish, lipid peroxidation and the risk of myocardial infarction and coronary, cardiovascular and any death in eastern Finnish men. Circulation 1995; 91: 645-55.
18. Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74: 130-6.
19. Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingam men and women. Arch Intern Med 1999; 159: 1077-80.
20. Blacher J, Benetos A, Kirzin JM, Malejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90: 591-5.
21. Greenland S. Modelling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-9.
22. Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7.
23. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
24. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 538-49.
25. Chowienczyk PJ, Watts GF, Cockkroft JR, Ritte JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 1430-2.
26. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-500.
27. Vaudo G, Marchesi S, Siepi D et al. Relevance of homocysteine on brachial flow-mediated vasodilatation and carotid and femoral intima-media thickness in patients with hypercholesterolemia. Am J Cardiol 2004; 93: 1413-6.
28. Mannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16: 25-30.
29. Norio R. Diseases in Finland and Scandinavia. In: Rothscild HR, ed. Biocultural Aspects of Disease. Orlando, FL: Academic Press Inc., 1981; 358-415.
30. Brattström L, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 1998; 98: 2520-6.
31. Rady PL, Tyring SK, Hudnall SD et al. Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 1999; 86: 380-4.